ENTITY
Keymed Biosciences

Keymed Biosciences (2162 HK)

104
Analysis
Health Care • China
Keymed Biosciences is a biotechnology company focused on the in-house discovery and development of innovative biological therapies for autoimmune diseases and oncology. Their pipeline includes over 50 programs, with key products like Kangyueda® (Stapokibart, CM310) for atopic dermatitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis. The company was founded in 2016 and is headquartered in Chengdu, China.
more
Exchange Announcement • 22 Sep 2026 17:03

2026 Interim Report

Exchange Announcement • 06 Sep 2026 18:31

List Of Directors And Their Roles And Functions

Exchange Announcement • 06 Sep 2026 18:29

Resignation Of Non-Executive Director

Exchange Announcement • 02 Sep 2026 21:03

Voluntary Announcement - Entered Into A Licensing Agreement In Relation To The Marketing Registration And Commercialization Of Stapokibart Injection In 18 Countries And Regions Including Southeast Asia And Central Asia

Exchange Announcement • 19 Aug 2026 21:31

Inside Information - Proposed Issue Of Rmb Shares And Listing On The Sci-Tech Board Of The Shanghai Stock Exchange

x